ValuEngine downgraded shares of Conatus Pharmaceuticals (NASDAQ:CNAT) from a sell rating to a strong sell rating in a research note issued to investors on Wednesday morning.

Several other analysts have also weighed in on CNAT. S&P Equity Research lifted their price objective on Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. Roth Capital started coverage on Conatus Pharmaceuticals in a report on Thursday, February 8th. They set a buy rating and a $20.00 price objective on the stock. SunTrust Banks decreased their price objective on Conatus Pharmaceuticals to $4.30 and set a buy rating on the stock in a report on Thursday, April 5th. HC Wainwright decreased their price objective on Conatus Pharmaceuticals from $17.00 to $15.00 and set a buy rating on the stock in a report on Thursday, April 5th. Finally, Oppenheimer set a $14.00 price objective on Conatus Pharmaceuticals and gave the stock a buy rating in a report on Thursday, April 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Conatus Pharmaceuticals presently has an average rating of Buy and a consensus target price of $12.00.

CNAT opened at $3.57 on Wednesday. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.47. Conatus Pharmaceuticals has a 12-month low of $3.44 and a 12-month high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.02. The firm had revenue of $8.80 million for the quarter, compared to analyst estimates of $9.60 million. Conatus Pharmaceuticals had a negative return on equity of 61.58% and a negative net margin of 49.17%. equities analysts predict that Conatus Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in CNAT. MPM Asset Management LLC grew its holdings in shares of Conatus Pharmaceuticals by 76.3% during the 4th quarter. MPM Asset Management LLC now owns 2,101,171 shares of the biotechnology company’s stock worth $9,707,000 after purchasing an additional 909,091 shares in the last quarter. State Street Corp acquired a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter worth approximately $2,092,000. Sterling Capital Management LLC bought a new position in shares of Conatus Pharmaceuticals during the 3rd quarter worth approximately $708,000. BlackRock Inc. lifted its position in shares of Conatus Pharmaceuticals by 6.2% during the 4th quarter. BlackRock Inc. now owns 1,593,395 shares of the biotechnology company’s stock worth $7,362,000 after buying an additional 93,015 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Conatus Pharmaceuticals by 26.2% during the 4th quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock worth $1,983,000 after buying an additional 89,179 shares during the period. 39.49% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Conatus Pharmaceuticals (CNAT) Downgraded by ValuEngine to “Strong Sell”” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2018/04/22/conatus-pharmaceuticals-cnat-downgraded-by-valuengine-to-strong-sell.html.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.